文献速递多重用药

老年高多重用药患者去处方:基层医疗整群随机试验

Deprescribing in older patients with hyperpolypharmacy: a cluster-randomised trial in primary care.
PubMed 文献 · Age Ageing · 2026-01-01

这项整群随机对照试验在58家药房纳入318例≥75岁、高多重用药且使用多剂量给药系统的患者,评估受训药师主导的去处方聚焦临床药物审查效果。

要点

  • 受训药师主导的去处方聚焦药物审查可增加高多重用药老年人的减停药物数。
  • 6个月时干预组人均减停2.5种药物,对照组1.7种,均差0.79(95%CI 0.29-1.28)。
  • 药物总数、健康问题及生活质量在6个月内未见显著组间差异。

核心结论

  • 受训药师开展去处方聚焦临床药物审查,可成功增加使用多剂量给药系统的高多重用药老年患者减停药物数。
  • 6个月观察期内未观察到健康问题或健康相关生活质量的变化。

研究设计与样本

  • 整群随机对照试验,58家药房参与,纳入318例患者(干预组155例,对照组163例)。
  • 纳入标准为年龄≥75岁、高多重用药且使用多剂量给药系统(MDD)。
  • 干预药房药师接受去处方聚焦临床药物审查培训,对照药房提供常规照护。
  • 主要结局为6个月后每例患者减少和停用药物的数量,采用广义线性混合模型分析。

主要发现

  • 健康问题及生活质量(EQ-5D-5L、EQ-VAS)未见显著组间差异。

临床怎么用

  • 对≥75岁、高多重用药且使用多剂量给药系统的基层老年患者,可考虑由受训药师开展去处方聚焦药物审查以促进减停药物。
  • 去处方干预后6个月内应关注药物总数及健康相关生活质量,现有证据未显示短期显著改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polypharmacy increases the risk of adverse drug events and potentially preventable hospital admissions. Deprescribing may reduce medication-related harm, and a clinical medication review (CMR) provides an opportunity to support this. OBJECTIVE: To investigate the effect of a deprescribing-focused CMR by trained pharmacists on the number of reduced and stopped medications among patients aged ≥75 years with hyperpolypharmacy using multidose-drug-dispensing (MDD)-systems. METHODS: In this cluster-randomised controlled trial, pharmacists were trained to perform a deprescribing-focused CMR, while control pharmacies provided usual care. Eligible patients were aged ≥75 years, had hyperpolypharmacy and used MDD. Dispensing data were used to determine the number of reduced and stopped medications per patient after 6 months (primary outcome). Secondary outcomes were: total number of medications, health problems and quality-of-life (EQ-5D-5L, EQ-VAS). A generalised linear mixed model was used for the primary outcome. RESULTS: A total of 318 patients from 58 pharmacies were enrolled (155 intervention, 163 control). At 6 months, patients in the intervention group had significantly more medications deprescribed than those in the control group (mean 2.5 vs. 1.7 per patient; mean difference 0.79, 95% CI 0.29-1.28; P = .002). There was no significant between-group difference in the total number of medications at 6 months (intervention -0.30 vs. control +0.12; P = .108). No significant differences were observed in health problems or quality-of-life. CONCLUSION: Deprescribing-focused CMRs by trained pharmacists successfully increased reduction and stopping of medications in older patients with hyperpolypharmacy using MDD-systems, while no changes in health problems or health-related quality of life could be observed over 6 months.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Baas G, Heringa M, Verdoorn S, et al. Deprescribing in older patients with hyperpolypharmacy: a cluster-randomised trial in primary care. Age Ageing. 2026. PMID: 42472621. doi:10.1093/ageing/afag209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。